A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein

Cell Research

Volumn 25, Issue 11, 2015, Pages 1237-1249

  Li, Yan ^a   Wan, Yuhua ^a,b,c   Liu, Peipei ^a   Zhao, Jincun ^d,h   Lu, Guangwen ^e   Qi, Jianxun ^a   Wang, Qihui ^c   Lu, Xuancheng ^f   Wu, Ying ^a   Liu, Wenjun ^a   Zhang, Buchang ^b   Yuen, Kwok Yung ^g   Perlman, Stanley ^d   Gao, George F ^a,b,c,f   Yan, Jinghua ^a,b,c  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b ANHUI UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d UNIVERSITY OF IOWA   (United States)

^e SICHUAN UNIVERSITY   (China)

^f CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^g THE UNIVERSITY OF HONG KONG   (Hong Kong)

^h GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

crystal structure; humanization; MERS CoV; neutralizing monoclonal antibody

Indexed keywords

CORONAVIRUS SPIKE GLYCOPROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CORONAVIRUS INFECTIONS; DRUG EFFECTS; IMMUNOLOGY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; MICE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS;

EID: 84946491594     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2015.113     Document Type: Article

References (41)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia N Engl J Med 2012 367 1814-1820
2. Chan JF, Li KS, To KK, Cheng VC, Chen H, Yuen KY. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?. J Infect 2012; 65: 477-489
3. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003; 362: 1353-1358
4. Health Protection Agency UKNCIt. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill 2013; 18: 20427
5. Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 2013; 382: 694-699
6. Su S, Wong G, Liu Y, Gao GF, Li S, Bi Y. MERS in South Korea and China: a potential outbreak threat ?. Lancet 2015; 385: 2349-2350
7. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500: 227-231
8. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69: 635-664
9. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 2009; 7: 226-236
10. Masters PS. The molecular biology of coronaviruses. Adv Virus Res 2006; 66: 193-292
11. Raj VS, Mou HH, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495: 251-254
12. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013; 11: 836-848
13. Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015; 23: 468-478
14. Wang N, Shi X, Jiang L, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23: 986-993
15. Gao J, Lu G, Qi J, et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol 2013; 87: 13134-13140
16. Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014; 5: 3067
17. Du L, Zhao G, Kou Z, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013; 87: 9939-9942
18. Du L, Kou Z, Ma C, et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERSCoV infection and induces strong neutralizing antibody responses: Implication for developing therapeutics and vaccines. PLoS One 2013; 8: e81587
19. Song F, Fux R, Provacia LB, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 2013; 87: 11950-11954
20. Tang XC, Agnihothram SS, Jiao Y, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA 2014; 111: E2018-E2026
21. Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014; 6: 234ra259
22. Pascal KE, Coleman CM, Mujica AO, et al. Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA 2015; 112: 8738-8743
23. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014; 111: 4970-4975
24. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19: 1313-1317
25. Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014; 14: 1090-1095
26. D'souza P, Walker G. Spotlight on chronic lymphocytic leukemia: A Pharma Matters report. Drugs Today (Barc) 2014; 50: 485-501
27. Murray J, Saxena S, Sharland M. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. Arch Dis Child 2014; 99: 469-473
28. Jacob J, Kirova YM. Locoregional breast radiotherapy and concurrent treatment with trastuzumab. Bull Cancer 2014; 101: 40-51
29. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514: 47-53
30. Bermingham A, Chand MA, Brown CS, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 2012; 17: 20290
31. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995; 34: 10474-10482
32. Muller YA, Chen Y, Christinger HW, et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 angstrom resolution and mutational analysis of the interface. Structure 1998; 6: 1153-1167
33. Faelber K, Kirchhofer D, Presta L, Kelley RF, Muller YA. The 1.85 Å resolution crystal structures of tissue factor in complex with humanized Fab D3h44 and of free humanized Fab D3h44: revisiting the solvation of antigen combining sites. J Mol Biol 2001; 313: 83-97
34. Karpusas M, Lucci J, Ferrant J, et al. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure 2001; 9: 321-329
35. Ying T, Du L, Ju TW, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 2014; 88: 7796-7805
36. Huang W, Samanta M, Crawford SE, et al. Identification of human single-chain antibodies with broad reactivity for noroviruses. Protein Eng Des Sel 2014; 27: 339-349
37. Houimel M. The analysis of VH and VL genes repertoires of Fab library built from peripheral B cells of human rabies virus vaccinated donors. Hum Immunol 2014; 75: 745-755
38. Avnir Y, Tallarico AS, Zhu Q, et al. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog 2014; 10: e1004103
39. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79: 10108-10125
40. Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013; 67: 130-140
41. Zheng BJ, Chan KW, Lin YP, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105: 8091-8096